FDA approves first interchangeable biosimilar insulin product
The Food and Drug Administration this week approved the first interchangeable biosimilar insulin product to treat diabetes. The product (Semglee) can be substituted for the previously approved biological insulin product Lantus to treat type 1 diabetes in children and type 1 or 2 diabetes in adults.
“This is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce health care costs,” said Acting FDA Commissioner Janet Woodcock, M.D.
For more information on biosimilar and interchangeable products, see the new FDA resources for health care providers.
Related News Articles
Headline
Access to quality mental and physical health services can be a complex challenge, but for individuals of color and people with severe or chronic mental…
Blog
EnglISH¿Qué pasa si una conversación puede cambiar, o incluso salvar, una vida? Esa fue la pregunta que AdventHealth buscó responder, cuando el sistema de…
Blog
ESPAÑOLWhat if one conversation can change, or even save, a life? That was the question AdventHealth sought to answer, as the health system launched a…
Headline
Terry Fulmer, Ph.D., R.N., president of the John A. Hartford Foundation, explains in a new blog how its "4Ms" care model aligns with AHA's Patient Safety…
Headline
AHA and the Institute for Diversity and Health Equity released the fifth and final installment in its five-part DEI Data Insights series, which highlights…
Chairperson's File
We know that health equity matters. But what exactly does the term mean? AHA’s Institute for Diversity and Health Equity defines “health equity” as “The fair…